Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2025-04-23

EMA Authorised: Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) (telmisartan) — Bayer AG

View source ↗

Summary

EMA authorised Kinzalmono, a telmisartan product, by Bayer AG for the treatment of hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kinzalmono (telmisartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Bayer AG. Decision date: 03/04/2025